XM levert geen diensten aan inwoners van de Verenigde Staten.

A
A

AstraZeneca

Nieuws

Reuters - 7 uur geleden

EMA Says CHMP Recommended 6 Extensions Of Indication For Medicines Including Wegovy

BRIEF-EMA Says CHMP Recommended 6 Extensions Of Indication For Medicines Including Wegovy March 31 (Reuters) - EMA: EMA SAYS CHMP RECOMMENDED 6 EXTENSIONS OF INDICATION FOR MEDICINES BREYANZI, ENTRESTO AND ITS DUPLICATE NEPARVIS, TENKASI, ULTOMIRIS AND WEGOVY
A
Reuters - 9 uur geleden

London stocks close out quarter higher as healthcare, consumer stocks gain

UPDATE 2-London stocks close out quarter higher as healthcare, consumer stocks gain For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. U.S. consumer spending falls in Feb Ocado climbs on patent row win FTSE 100 gains for the quarter, though falls for March Beazley gains after UBS double upgrade FTSE 100 up 0.2%, FTSE 250 adds 0.1% Updates to market close, adds fresh comments By Johann M Cherian and Shashwat Chauhan March 31 (Reuters) - Lon
A
B
D
E
G
O
U
U
Reuters - 2 dagen geleden

Astrazeneca Completes KYM Agreement For CMG901

BRIEF-Astrazeneca Completes KYM Agreement For CMG901 March 30 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 CMG901 IS CURRENTLY BEING EVALUATED IN A PHASE I TRIAL FOR TREATMENT OF CLAUDIN 18.2-POSITIVE SOLID TUMOURS, INCLUDING GASTRIC CANCER PRELIMINARY RESULTS FROM
A
Reuters - 2 dagen geleden

Compass Group, AstraZeneca Expands Activities Focused On Innovation

BRIEF-Compass Group, AstraZeneca Expands Activities Focused On Innovation March 29 (Reuters) - AstraZeneca PLC AZN.L : COMPASS GROUP AND ASTRAZENECA EXPAND ACTIVITIES FOCUSED ON INNOVATION AND SHARED SUCCESS Source text for Eikon: ID:nBw5dF8sQa Further company coverage: AZN.L
A
C
Reuters - 2 dagen geleden

Boehringer's profit up as Jardiance gains offset higher costs

UPDATE 1-Boehringer's profit up as Jardiance gains offset higher costs Adds CFO comment, details on earnings FRANKFURT, March 29 (Reuters) - German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year ear
A
Reuters - 2 dagen geleden

Boehringer's profit up 1.4% as Jardiance gains offset impairments

Boehringer's profit up 1.4% as Jardiance gains offset impairments FRANKFURT, March 29 (Reuters) - German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy costs and the effect of write-downs on development projects. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier.
A
Reuters - 4 dagen geleden

UK Stocks-Factors to watch on March 28

UK Stocks-Factors to watch on March 28 March 28 - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.29%. * CINEWORLD: Creditors of British cinema operator Cineworld Group PLC CINE.L are outlining plans for a new board and executive team after nine years under CEO Mooky Greidinger and his deputy Israel Greidinger, Bloomberg News reported.
A
B
C
W
U
Reuters - 4 dagen geleden

Eplontersen Demonstrated Sustained Benefit In Phase III Trial For Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Through 66 Weeks

BRIEF-Eplontersen Demonstrated Sustained Benefit In Phase III Trial For Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Through 66 Weeks March 27 (Reuters) - AstraZeneca PLC AZN.L : EPLONTERSEN DEMONSTRATED SUSTAINED BENEFIT IN PHASE III TRIAL FOR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY (ATTRV-PN) THROUGH 66 WEEKS Source t
A
Reuters - 4 dagen geleden

Wall St set for higher open as SVB deal soothes frayed nerves

US STOCKS-Wall St set for higher open as SVB deal soothes frayed nerves For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. First Citizens to buy SVB assets; shares jump Regional, large bank stocks jump Tesla gains as Barclays forecasts upbeat deliveries Futures up: Dow 0.63%, S&P 0.62%, Nasdaq 0.34% Updates prices, adds details By Amruta Khandekar and Ankika Biswas March 27 (Reuters) - Wall Street's main indexes were set to open higher on
A
C
D
T
U
U
U
F
Reuters - 4 dagen geleden

US stock futures climb as banking crisis fears ebb after SVB deal

US STOCKS-Futures climb as banking crisis fears ebb after SVB deal For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. First Citizens to buy SVB assets; shares jump Regional, large bank stocks jump Futures up: Dow 0.59%, S&P 0.59%, Nasdaq 0.33% Updates prices throughout; adds details, comments By Amruta Khandekar and Ankika Biswas March 27 (Reuters) - U.S.
A
C
D
H
U
U
U
F
Reuters - 4 dagen geleden

UK stocks finish higher as banks, AstraZeneca climb

UPDATE 2-UK stocks finish higher as banks, AstraZeneca climb For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. AstraZeneca rises on late-stage drug trial success UK GDP eyed later in the week FTSE 100 up 0.9%, FTSE 250 adds 0.2% New throughout, updates prices, market activity and comments to close By Johann M Cherian and Shashwat Chauhan March 27 (Reuters) - London stocks rose on Monday with the FTSE 100 finishing nearly 1 % higher as ban
A
A
C
E
S
N
U
Reuters - 4 dagen geleden

Novartis buoyed by trial success in early-stage breast cancer

UPDATE 2-Novartis buoyed by trial success in early-stage breast cancer Kisqali trial stopped after clear benefit shows early Shares gain 5.8% to four-week high Breast cancer drug key to Swiss group's growth ambitions Adds analyst comment, industry background By Ludwig Burger FRANKFURT, March 27 (Reuters) - Novartis's NOVN.S Kisqali breast cancer drug cut the risk of recurrence in women who were diagnosed at an early stage of the disease in a pivotal trial, providing a confidence boost for the dr
A
N
P
Reuters - 5 dagen geleden

Astrazeneca Says Eplontersen Demonstrated Sustained Benefit In Phase III Trial For PN

BRIEF-Astrazeneca Says Eplontersen Demonstrated Sustained Benefit In Phase III Trial For ATTRV-PN March 27 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA - EPLONTERSEN DEMONSTRATED SUSTAINED BENEFIT IN PHASE III TRIAL FOR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY (ATTRV-PN) THROUGH 66 WEEKS ASTRAZENECA - EPLONTERSEN CONTINUED TO DEMONSTRATE A SAFETY AND TOLERABILITY PROFILE CONSISTENT WITH THAT OBSERVED AT 35 WEEKS.
A
Reuters - 1 week geleden

Astrazeneca Says Calquence Granted First Regulatory Approval In China For Adults With Previously Treated Mantle Cell Lymphoma

BRIEF-Astrazeneca Says Calquence Granted First Regulatory Approval In China For Adults With Previously Treated Mantle Cell Lymphoma March 23 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA - CALQUENCE GRANTED FIRST REGULATORY APPROVAL IN CHINA FOR ADULTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA Source text for Eikon: [ID:] Further company cover
A
Reuters - 1 week geleden

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data

UPDATE 5-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data Drug meets primary and all secondary goals in COPD trial Previous peak sales estimate of 13 bln euros was without COPD Drug could be first new COPD treatment in over a decade Adds Regeneron price, paragraph 5 By Ludwig Burger March 23 (Reuters) - Sanofi's SASY.PA asthma drug Dupixent met all targets in a trial to treat "smoker's lung", potentially adding billions to the French drugmaker's growth prospects, but also underscoring
A
R
S
Reuters - 2 weken geleden

How GSK plans to replenish its depleted medicine cabinet

FOCUS-How GSK plans to replenish its depleted medicine cabinet GSK has overhauled R&D dept since Walmsley became CEO Top scientist Wood says R&D dept now delivering results Wood says GSK now de-emphasizing oncology British peer Astra has strong oncology portfolio Investor concerns over GSK pipeline reflect in share price-analysts By Maggie Fick STEVENAGE, England, March 15 (Reuters) - GSK's GSK.L chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing a
A
C
G
N
P
U
Reuters - 3 weken geleden

SVB shock could have chilling effect on British biotech sector

UPDATE 1-SVB shock could have chilling effect on British biotech sector UK deal averted disaster for biotech start-ups Some 40% of UK biotech firms were banking with SVB UK aims to be life sciences "superpower" Adds details about UK biotech that was exposed to SVB By Natalie Grover and Maggie Fick LONDON, March 13 (Reuters) - HSBC HSBA.L 's rescue of the British arm of Silicon Valley Bank saved the heavily-exposed UK biotech sector from collapse, but the fallout could hamper funding in a sector
A
B
G
H
Reuters - 3 weken geleden

SVB shock could have chilling effect on British biotech sector

SVB shock could have chilling effect on British biotech sector UK deal averted disaster for biotech start-ups Some 40% of UK biotech firms were banking with SVB UK aims to be life sciences "superpower" By Natalie Grover and Maggie Fick LONDON, March 13 (Reuters) - HSBC HSBA.L 's rescue of the British arm of Silicon Valley Bank saved the heavily-exposed UK biotech sector from collapse, but the fallout could hamper funding in a sector the government sees as key to future economic growth, industry
A
B
G
H
Reuters - 3 weken geleden

Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spree

FACTBOX-Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spree March 13 (Reuters) - Pfizer Inc PFE.N struck a $43 billion deal to buy Seagen Inc SGEN.O in the U.S. drugmaker's biggest in a string of acquisitions undertaken after a sales windfall from its COVID-19 products. The drugmaker has a history of transformative deals even before the pandemic such as spinning off its portfolio of off-patent drugs.
A
G
M
P
Reuters - 3 weken geleden

Imfinzi Significantly Improved Event-Free Survival In Aegean Phase Iii Trial For Patients With Resectable Non-Small Cell Lung Cancer

BRIEF-Imfinzi Significantly Improved Event-Free Survival In Aegean Phase Iii Trial For Patients With Resectable Non-Small Cell Lung Cancer March 9 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI SIGNIFICANTLY IMPROVED EVENT-FREE SURVIVAL IN AEGEAN PHASE III TRIAL FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER Source text for Eikon: ID:nBwlKlGG
A

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

We gebruiken cookies om u de beste ervaring op onze website te bieden. Meer lezen of wijzig uw cookie-instellingen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.